Humana (HUM) vs Progyny (PGNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Progyny (PGNY) has outperformed Humana (HUM) over the past year, gaining 37.8% versus a gain of 29.9%. Over five years, HUM leads with a -12.2% price change compared with -50.8% for PGNY. Humana is the larger company by market cap ($46.49 billion vs $2.14 billion), about 21.8 times the size.
On valuation, Progyny trades at a lower forward P/E (12.0x vs 23.2x for Humana). Humana pays a dividend yielding 0.91%, while Progyny does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUM | PGNY |
|---|---|---|
| Share price | $387.12 | $27.83 |
| Market cap | $46.49B | $2.14B |
| 1-day change | -2.37% | +1.02% |
| YTD return | +51.14% | +7.28% |
| 1-year return | +29.89% | +37.75% |
| 5-year return | -12.22% | -50.79% |
| P/E ratio (TTM) | 36.59 | 30.25 |
| Forward P/E | 23.22 | 12.00 |
| EPS (TTM) | $10.58 | $0.92 |
| Dividend yield | 0.91% | 0.00% |
| Annual dividend | $3.54 | $0.00 |
| Revenue (latest FY) | $129.66B | — |
| Revenue growth (YoY) | +10.11% | — |
| Net income (latest FY) | $1.19B | — |
| Operating margin | 2.09% | — |
| Net margin | 0.92% | — |
| 52-week high | $428.88 | $33.07 |
| 52-week low | $163.11 | $16.10 |
| Distance from 52-week high | -9.74% | -15.83% |
| Analyst consensus | buy | none |
| Avg. price target upside | +9.46% | +23.68% |
| Average volume | 1.24M | 1.15M |
| Shares outstanding | 120.08M | 76.73M |
| Employees | 67,060 | 835 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Humana is about 21.8 times larger than Progyny by market value ($46.49B vs $2.14B).
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
About Progyny
PGNY stock →Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.
Health Care · Misc Health and Biotechnology Services · 835 employees
HUM vs PGNY FAQ
Which is bigger, Humana or Progyny?
Humana (HUM) is larger, with a market capitalization of $46.49B compared with $2.14B for Progyny (PGNY).
Which stock has performed better over the past year, HUM or PGNY?
PGNY returned +37.75% over the past 12 months, compared with +29.89% for HUM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HUM or PGNY?
PGNY has the lower trailing P/E at 30.3, versus 36.6 for HUM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Humana or Progyny?
Humana pays a dividend yielding 0.91%, while Progyny does not currently pay a regular dividend.
Are Humana and Progyny in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Humana and Misc Health and Biotechnology Services for Progyny.